TherapeuticsMD (TXMD) Free Cash Flow Growth (1y) (2011 - 2026)
TherapeuticsMD (TXMD) Free Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.69 Bn | 87.82 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.96 Bn | 32.22 Bn | 1.97 Bn | 10.34% |
| 3 | Zoetis | 32.61 Bn | 30.67 Bn | 1.62 Bn | -13.65% |
| 4 | Takeda Pharmaceutical | 27.56 Bn | 23.49 Bn | 4.39 Bn | 56.40% |
| 5 | United Therapeutics | 23.06 Bn | 20.91 Bn | 648.10 Mn | -5.85% |
| 6 | RedHill Biopharma | 22.43 Bn | 22.43 Bn | - | - |
| 7 | Viatris | 20.25 Bn | 18.44 Bn | 1.16 Bn | -29.32% |
| 8 | Neurocrine Biosciences | 17.75 Bn | 16.43 Bn | 800.70 Mn | 166.91% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 44.93% |
| 10 | TherapeuticsMD | 284,239.99 | -8.13 Mn | - | 35.05% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 35.05% |
| Dec 31, 2025 | 2,105.88% |
| Sep 30, 2025 | 1,507.04% |
| Jun 30, 2025 | -73.78% |
| Mar 31, 2025 | 405.24% |
| Dec 31, 2024 | 100.23% |
| Sep 30, 2024 | 98.66% |
| Jun 30, 2024 | 149.95% |
| Mar 31, 2024 | 97.37% |
| Dec 31, 2023 | -132.14% |
| Sep 30, 2023 | -129.96% |
| Jun 30, 2023 | 85.95% |
| Mar 31, 2023 | 51.32% |
| Dec 31, 2022 | -52.87% |
| Sep 30, 2022 | 146.43% |
| Jun 30, 2022 | 22.10% |
| Mar 31, 2022 | 53.40% |
| Dec 31, 2021 | 257.25% |
| Sep 30, 2021 | -12.01% |
| Jun 30, 2021 | 52.51% |